PROTAGONIST THERAPEUTICS INC (PTGX) Stock Price & Overview
NASDAQ:PTGX • US74366E1029
The current stock price of PTGX is 96.83 USD. Today PTGX is up by 0.18%. In the past month the price increased by 14.4%. In the past year, price increased by 76.45%.
PTGX Key Statistics
- Market Cap
- 6.179B
- P/E
- N/A
- Fwd P/E
- 51.34
- EPS (TTM)
- -2.05
- Dividend Yield
- N/A
PTGX Stock Performance
PTGX Stock Chart
PTGX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to PTGX. When comparing the yearly performance of all stocks, PTGX is one of the better performing stocks in the market, outperforming 89.58% of all stocks.
PTGX Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to PTGX. While PTGX has a great health rating, there are worries on its profitability.
PTGX Earnings
On February 25, 2026 PTGX reported an EPS of -0.69 and a revenue of 7.44M. The company missed EPS expectations (-28.03% surprise) and missed revenue expectations (-18.32% surprise).
PTGX Forecast & Estimates
19 analysts have analysed PTGX and the average price target is 102.55 USD. This implies a price increase of 5.91% is expected in the next year compared to the current price of 96.83.
For the next year, analysts expect an EPS growth of 192.01% and a revenue growth 619.9% for PTGX
PTGX Groups
Sector & Classification
PTGX Financial Highlights
Over the last trailing twelve months PTGX reported a non-GAAP Earnings per Share(EPS) of -2.05. The EPS decreased by -148.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.48% | ||
| ROE | -21.17% | ||
| Debt/Equity | 0 |
PTGX Ownership
PTGX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.31 | 402.17B | ||
| AMGN | AMGEN INC | 16.56 | 203.213B | ||
| GILD | GILEAD SCIENCES INC | 16.84 | 182.029B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.99 | 117.075B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.65 | 82.631B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.32 | 42.915B | ||
| INSM | INSMED INC | N/A | 30.852B | ||
| NTRA | NATERA INC | N/A | 29.086B | ||
| BIIB | BIOGEN INC | 11.77 | 27.626B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.2 | 23.193B | ||
| MRNA | MODERNA INC | N/A | 22.014B | ||
| EXAS | EXACT SCIENCES CORP | 340.98 | 19.797B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.775B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PTGX
Company Profile
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark California, California and currently employs 132 full-time employees. The company went IPO on 2016-08-11. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The firm also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
Company Info
IPO: 2016-08-11
PROTAGONIST THERAPEUTICS INC
7707 Gateway Blvd Ste 140
Newark California CALIFORNIA 94560 US
CEO: Dinesh V. Patel
Employees: 132
Phone: 13026365401
PROTAGONIST THERAPEUTICS INC / PTGX FAQ
Can you describe the business of PROTAGONIST THERAPEUTICS INC?
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark California, California and currently employs 132 full-time employees. The company went IPO on 2016-08-11. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The firm also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
What is the current price of PTGX stock?
The current stock price of PTGX is 96.83 USD. The price increased by 0.18% in the last trading session.
Does PROTAGONIST THERAPEUTICS INC pay dividends?
PTGX does not pay a dividend.
What is the ChartMill rating of PROTAGONIST THERAPEUTICS INC stock?
PTGX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Can you provide the PE ratio for PTGX stock?
PROTAGONIST THERAPEUTICS INC (PTGX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.05).
Is PROTAGONIST THERAPEUTICS INC (PTGX) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PTGX.
Can you provide the market cap for PROTAGONIST THERAPEUTICS INC?
PROTAGONIST THERAPEUTICS INC (PTGX) has a market capitalization of 6.18B USD. This makes PTGX a Mid Cap stock.